Zaltrap

Zaltrap Dosage/Direction for Use

aflibercept

Manufacturer:

sanofi-aventis

Distributor:

DKSH
Full Prescribing Info
Dosage/Direction for Use
ZALTRAP should be administered under the supervision of a physician experienced in the use of antineoplastic medicinal products.
Posology: The recommended dose of ZALTRAP, administered as an intravenous infusion over 1 hour, is 4 mg/kg of body weight, followed by the FOLFIRI regimen. This is considered as one treatment cycle.
The FOLFIRI regimen to be used is irinotecan 180 mg/m2 intravenous infusion over 90 minutes and folinic acid (dl racemic) 400 mg/m2 intravenous infusion over 2 hours at the same time on day 1 using a Y-line, followed by 5-fluorouracil (5-FU) 400 mg/m2 intravenous bolus, followed by 5-FU 2400 mg/m2 continuous intravenous infusion over 46 hours.
The treatment cycle is repeated every 2 weeks.
ZALTRAP treatment should be continued until disease progression or unacceptable toxicity occurs.
Dose Modification: ZALTRAP should be discontinued for (see Precautions): Severe haemorrhage; Gastrointestinal (GI) perforation; Fistula formation; Hypertension that is not adequately controlled with anti-hypertensive therapy or occurrence of hypertensive crisis or hypertensive; Cardiac failure and ejection fraction decreased; Arterial thromboembolic events (ATE); Grade 4 venous thromboembolic events (including pulmonary embolism); Nephrotic syndrome or thrombotic microangiopathy (TMA); Severe hypersensitivity reactions (including bronchospasm, dyspnoea, angioedema, and anaphylaxis) (see Contraindications and Precautions); Compromised wound healing requiring medical intervention; Posterior reversible encephalopathy syndrome (PRES) (also known as reversible posterior leukoencephalopathy syndrome (RPLS)).
ZALTRAP should be temporarily suspended for at least 4 weeks prior to elective surgery (see Precautions). (See Table 4.)

Click on icon to see table/diagram/image

For additional toxicities related to irinotecan, 5-FU, or folinic acid, refer to the current respective summary of product characteristics.
Special Populations: Older People: In the pivotal MCRC study, 28.2% of patients were aged ≥ 65 and < 75 and 5.4% of patients were aged ≥ 75. No dose adjustments of ZALTRAP is required in the older people.
Hepatic Impairment: There have been no formal studies with ZALTRAP in patients with hepatic impairment (see Pharmacology: Pharmacokinetics under Actions). Clinical data suggest that no change in aflibercept dose is required in patients with mild to moderate hepatic impairment. There are no data regarding the administration of aflibercept in patients with severe hepatic impairment.
Renal Impairment: There have been no formal studies with ZALTRAP in patients with renal impairment (see Pharmacology: Pharmacokinetics under Actions). Clinical data suggest that no change in starting dose is required in patients with mild to moderate renal impairment. There are very limited data in patients with severe renal impairment; therefore, these patients should be treated with caution.
Paediatric Population: There is no relevant use of ZALTRAP in the paediatric population for the indication of metastatic colorectal cancer.
Method of Administration: ZALTRAP is to be administered only as an intravenous infusion over 1 hour. Due to hyperosmolality (1000 mOsmol/kg) of the ZALTRAP concentrate, undiluted ZALTRAP concentrate must not be administered as an intravenous push or bolus. ZALTRAP must not be administered as an intravitreal injection (see Contraindications and Precautions).
Each vial of concentrate for solution for infusion is for single use (single-dose) only.
Diluted solutions of ZALTRAP should be administered using infusion sets containing a 0.2 micron polyethersulfone filter.
The infusion sets should be made of one of the following materials: polyvinyl chloride (PVC) containing bis(2-ethylhexyl) phthalate (DEHP), DEHP free PVC containing trioctyl-trimellitate (TOTM), polypropylene, polyethylene lined PVC, polyurethane.
Filters made of polyvinylidene fluoride (PVDF) or nylon must not be used.
Precautions to be taken before handling or administering the medicinal product: For instructions on dilution of the medicinal product before administration, see Special Precautions for Disposal and Other Handling under Cautions for Usage.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in